Experimental Drug Shows Favorable Results Against Brain Cancer

by: cancercompass

Biotechnology company Angiochem, Inc. recently announced its drug ANG1005 showed favorable results in two separate clinical studies of more than 100 patients with progressive brain gliomas, including recurrent glioblastoma, and in patients with progressive brain metastases. Data from these trials was presented October 18th at the Society for Neuroscience annual meeting in Chicago.

According to an Angiochem press release, greater than 70% of patients receiving ANG1005 in therapeutic doses experienced disease control, with more than half showing a reduction in tumor size. In addition, 78% of patients with taxane resistant tumors responded to ANG1005, which means there is potential for the drug to help against resistant tumors.

Another major finding cited in the press release was the drug's ability to cross the blood-brain barrier without central nervous system toxicity or immunogenicity. Patient tumor brain samples showed ANG1005 was present, which was proof the drug crossed the blood-brain barrier to concentrate in the tumor.

Scientists have observed similar trends in patient responses during the ongoing Phase 1/2 recurrent glioblastoma clinical trial with roughly 65% of patients experiencing disease control to date.

Have you or a loved one undergone experimental cancer treatments? Discuss your experiences at the CancerCompass Clinical Trials & Research Message Board.